Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > ARCHIVE
ARCHIVE
- JPA President Kodama to Explain about Leaked Copy of His Appeal at General Assembly
August 15, 2011
- NCCHD Creates Pediatric Clinical Trial Network of 27 Facilities
August 15, 2011
- MSD Invites Former JPMA Director General as Compliance Adviser
August 15, 2011
- Kowa Obtains Marketing Approval for Pitavastatin in Mexico
August 15, 2011
- Gov't Council Submits 4th Science & Technology Basic Plan
August 15, 2011
- Kyowa Kirin Aims for 70% Increase in Sales for UK Subsidiary ProStrakan by 2013
August 15, 2011
- AZ's New Antiplatelet Agent Ticagrelor Approved by the FDA
August 15, 2011
- Shionogi Completes New Core Research Facility in Toyonaka
August 15, 2011
- Top-100 Product Ranking Affected by Premium, Price Revisions
August 15, 2011
- RoACTEMRA Approved for sJIA in Children 2 Years or Older in Europe
August 15, 2011
- Tella Announces Research Results for Dendritic Cell Vaccine Therapy
August 15, 2011
- Aricept Has Overwhelming Advantage in AD Market in Japan: Mr Honda
August 15, 2011
- Roche's Tarceva Receives Positive Opinion from CHMP for 1st-Line NSCLC Therapy
August 15, 2011
- Korosho Starts Inviting Requests for Approval of Unapproved Drugs/Indications
August 15, 2011
- Yakult Gains Option Rights to Anticancer Drug from Proacta
August 15, 2011
- EC Approves Acquisition of Nycomed by Takeda
August 15, 2011
- First Aid for Choking
August 15, 2011
- Takeda to Start Multinational PIII Trial for TAK-875 in FY2011
August 8, 2011
- R&D Spending Fell, Discontinued Clinical Trials Increased in 2010: Thomson Reuters
August 8, 2011
- Kyowa Kirin Files for PD Treatment KW-6500 in Japan
August 8, 2011
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…